Dark

SGEN
Seagen Inc. Common Stock
stock NASDAQ

Inactive

Dec 13, 2023

228.74USD-0.070%(-0.16)20,075,430

Pre-market

0.00USD-100.000%(-228.90)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

10:29AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022 Benzinga

06:34AM EST Morgan Stanley Upgrades Seagen to Overweight, Announces $175 Price Target Benzinga

Jan 19, 2022

09:31AM EST Seagen's SEA-CD40 Combo Regime Shows Preliminary Antitumor Activity In Pancreatic Cancer Benzinga

Jan 18, 2022

05:03PM EST Seagen Reports Data From SEA-CD40 In Combination With Other Therapies In Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) At American Society of Clinical Oncology Gastrointestinal Cancers Symposium Benzinga

12:05PM EST Where Seagen Stands With Analysts Benzinga

10:42AM EST Morgan Stanley Maintains Equal-Weight on Seagen, Lowers Price Target to $178 Benzinga

08:00AM EST Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022 Business Wire

Dec 20, 2021

08:00AM EST Seagen to Present at the J.P. Morgan Healthcare Conference Business Wire

Dec 17, 2021

07:03AM EST Astellas, Seagen Announce Positive CHMP Opinion For PADCEV RTTNews

06:49AM EST Astellas And Seagen Get Positive CHMP Opinion For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer RTTNews

06:41AM EST Seagen, Astellas Pharma Reports European Medicines Agency's Committee For Medicinal Products For Human Use Gave Positive Opinion For Co.'s PADCEV Benzinga

06:40AM EST Astellas and Seagen Receive Positive CHMP Opinion for PADCEV(tm) (enfortumab PR Newswire

06:40AM EST Astellas and Seagen Receive Positive CHMP Opinion for PADCEV(tm) (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer Business Wire

Dec 13, 2021

12:54PM EST Seagen Late Sunday Announced Prelim. Results From Phase 2 Trial Of ADCETRIS In Novel Combo Of Agents For Patients With Advanced Stage Classical Hodgkin Lymphoma: Showed 'Complete Response Rate of 88%, Overall Response Rate of 93%' Benzinga

Dec 9, 2021

09:45PM EST Seagen Tukysa Maintains Survival Benefit, Delays Cancer Progression In The Brain In Breast Cancer Patients Benzinga

Nov 9, 2021

01:35PM EST Where Seagen Stands With Analysts Benzinga

12:02PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 Benzinga

11:45AM EST Wolfe Research Initiates Coverage On Seagen with Peer Perform Rating, Announces Price Target of $195 Benzinga

08:54AM EST Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting Business Wire

Oct 29, 2021

12:13PM EDT Expert Ratings For Seagen Benzinga

10:22AM EDT Morgan Stanley Maintains Equal-Weight on Seagen, Raises Price Target to $181 Benzinga

08:00AM EDT The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs Benzinga

07:46AM EDT Oppenheimer Maintains Outperform on Seagen, Raises Price Target to $198 Benzinga

Oct 28, 2021

04:16PM EDT Seagen Q3 Loss/share $1.61 Vs. Profit $3.50 Year Ago RTTNews

04:06PM EDT Seagen Raises FY21 Royalty Revenues Guidance From $125M-$135M To $140M-$150M Benzinga

04:05PM EDT Seattle Genetics Q3 EPS $(1.61) May Not Compare To $(0.57) Estimate, Sales $424.06M Beat $384.65M Estimate Benzinga

04:02PM EDT Seagen Reports Third Quarter 2021 Financial Results Business Wire

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 27, 2021

10:26AM EDT Seattle Genetics's Earnings Outlook Benzinga

07:37AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:26AM EDT SVB Leerink Maintains Outperform on Seagen, Raises Price Target to $200 Benzinga

Oct 15, 2021

10:45AM EDT Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings Benzinga

Oct 12, 2021

08:04AM EDT Seagen And Astellas Complete Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab RTTNews

08:03AM EDT Astellas Closes Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab As Urothelial Cancer Treatment RTTNews

08:02AM EDT Seagen And Astellas Complete Enrollment In EV-103 Trial Cohort K Combining PADCEV With Pembrolizumab As First-Line Treatment For Advanced Urothelial Cancer Benzinga

08:00AM EDT PADCEV(r) (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer PR Newswire

08:00AM EDT Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV(r) (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer Business Wire

Oct 7, 2021

08:00AM EDT Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021 Business Wire

Oct 1, 2021

02:29PM EDT Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates Benzinga

Sep 28, 2021

08:06AM EDT Seagen Completes Enrollment In Phase 2 MOUNTAINEER Clinical Trial Of TUKYSA In Combination With Trastuzumab RTTNews

08:05AM EDT Seagen Reports Last Patient Enrolled In Phase 2 MOUNTAINEER Trial Evaluating TUKYSA Regimen In HER2-Positive Metastatic Colorectal Cancer Benzinga

08:00AM EDT Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA(r) (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer Business Wire

Sep 27, 2021

07:46AM EDT RBC Capital Maintains Sector Perform on Seagen, Raises Price Target to $154 Benzinga

03:40AM EDT Japan's Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) announced Monday that PADCEV (enfortumab vedotin) has received approval from Japan's Ministry of Health, Labour and Welfare or MHLW. The approval is for radically unresectable urothelial carcinoma that has progressed after anti-cancer chemotherapy. The New Drug Application received priority review. RTTNews

03:03AM EDT Astellas Pharma Says Japan's MHLW Approves PADCEV For Advanced Urothelial Cancer RTTNews

03:00AM EDT Japan's MHLW Approves PADCEV(r) (enfortumab vedotin) for Advanced Urothelial PR Newswire

03:00AM EDT Japan's MHLW Approves PADCEV(r) (enfortumab vedotin) for Advanced Urothelial Cancer Business Wire

Sep 22, 2021

04:45AM EDT SVB Leerink Maintains Outperform on Seagen, Lowers Price Target to $190 Benzinga

Sep 21, 2021

11:39AM EDT Why Genmab's Stock Is Trading Higher Today Benzinga

11:37AM EDT Why Seagen's Stock Is Trading Higher Today Benzinga

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Sep 20, 2021

05:05PM EDT Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK(tm) (tisotumab vedotin-tftv) Approval Business Wire

05:03PM EDT Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK(tm) (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer Business Wire

05:01PM EDT Seagen, Genmab Report FDA Accelerated Approval For TIVDAK In Previously Treated Recurrent, Metastatic Cervical Cancer Benzinga

05:00PM EDT Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK(tm) (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer Business Wire

07:54AM EDT 07:54 Monday, September 20, 2021William Blair (RTTNews) - William Blair Reiterates Seagen Inc (SGEN) At Outperform RTTNews

06:47AM EDT Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer Benzinga

Sep 19, 2021

12:01PM EDT Seagen And Genmab Present Interim Results From InnovaTV 205 Study For Tisotumab Vedotin Combination Therapy RTTNews

11:30AM EDT Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021 Business Wire

Sep 9, 2021

08:00AM EDT Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Business Wire

Sep 8, 2021

08:07AM EDT Seagen To Highlight Research From 16 Presentations Across Multiple Tumor Types At ESMO 2021 Benzinga

Aug 24, 2021

09:56AM EDT A Look Into Seagen's Price Over Earnings Benzinga

Aug 9, 2021

12:02PM EDT Seagen Bets On China's ADC In $2.6B Cancer Deal Benzinga

06:53AM EDT Biotechnology company Seagen Inc. (SGEN) and Chinese biopharmaceutical company RemeGen Co., Ltd. on Monday said they have entered into a licensing agreement for RemeGen's disitamab vedotin. RTTNews

06:07AM EDT Seagen, RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin; Seagen to Make $200M Upfront Payment to License Rights to Disitamab Vedotin Benzinga

06:04AM EDT Seagen And RemeGen Announce Licensing Deal To Develop Disitamab Vedotin RTTNews

06:03AM EDT Seagen, RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin; Seagen to Make $200M Upfront Payment to License Rights to Disitamab Vedotin Benzinga

06:00AM EDT Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin Business Wire

Jul 29, 2021

04:17PM EDT Seattle Genetics Sees FY21 ADCETRIS Sales $675M-$700M, Sees PADCEV Sales $310M-$325M, Sees TUKYSA Sales $300M-$315M, Sees Royalty Sales $125M-$135M Benzinga

04:15PM EDT Seattle Genetics Q2 EPS $(0.47) Beats $(0.60) Estimate, Sales $388.48M Beat $355.03M Estimate Benzinga

04:11PM EDT Seagen Q2 Loss/share $0.47 Vs. Loss $0.12 Year Ago RTTNews

04:02PM EDT Seagen Reports Second Quarter 2021 Financial Results Business Wire

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 16, 2021

09:04AM EDT Morgan Stanley Maintains Equal-Weight on Seagen, Lowers Price Target to $167 Benzinga

Jul 12, 2021

06:48AM EDT Astellas - Seagen's PADCEV Wins Full FDA Approval And Expanded Label In Tough-To-Treat Urothelial Cancer Benzinga

Jul 9, 2021

02:12PM EDT Seagen Says FDA Grants Regular Approval, Expands Indication For PADCEV For Patients With Locally Advanced Or Metastatic Urothelial Cancer Benzinga

02:10PM EDT (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire

02:10PM EDT U.S. FDA Grants Regular Approval and Expands Indication for PADCEV(r) (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer Business Wire

Jul 8, 2021

08:00AM EDT Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021 Business Wire

Jun 7, 2021

06:32AM EDT SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma Benzinga

Jun 3, 2021

08:27AM EDT Updated Analysis Show Seagen's Tukysa Extended Median OS to Two Years with Benefits Maintained in Breast Cancer Benzinga

06:02AM EDT Seagen Announces Long-Term Results from TUKYSA Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting Benzinga

Jun 2, 2021

08:00AM EDT Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference Business Wire

May 19, 2021

05:05PM EDT (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy PR Newswire

May 17, 2021

12:04PM EDT Evercore ISI Group Initiates Coverage On Seagen with In-Line Rating, Announces Price Target of $153 Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

Apr 29, 2021

05:06PM EDT Recap: Seagen Q1 Earnings Benzinga

04:08PM EDT Seagen Q1 Loss/share $0.67 Vs. Loss $0.98 Year Ago RTTNews

04:02PM EDT Seagen Reports First Quarter 2021 Financial Results Business Wire

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 28, 2021

10:55AM EDT Seattle Genetics's Earnings Outlook Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 19, 2021

09:11AM EDT Seagen Inc. (SGEN) and Astellas Pharma Inc. said that the U.S. Food and Drug Administration has accepted two supplemental biologics license applications for padcev or enfortumab vedotin-ejfv in locally advanced or metastatic urothelial cancer. RTTNews

08:04AM EDT Astellas And Seagen Announce US FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer Benzinga

08:03AM EDT Astellas And Seagen Announce FDA Acceptance Of Two Supplemental Biologics License Applications For PADCEV RTTNews

08:02AM EDT License Applications for PADCEV(r) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire

08:00AM EDT Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV(r) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer Business Wire

Apr 9, 2021

04:04PM EDT Seagen And Genmab Announced That The FDA Filing Acceptance For Priority Review Of Their Tisotumab Vedotin Biologics License Application For Patients With Recurrent Or Metastatic Cervical Cancer Benzinga

04:00PM EDT Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer Business Wire

04:00PM EDT Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer Business Wire

08:05AM EDT Seagen Says Will Highlight Data From Novel Targeted Therapies At AACR Benzinga

08:00AM EDT Seagen to Highlight Data from Novel Targeted Therapies at AACR Business Wire

Apr 7, 2021

08:00AM EDT Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021 Business Wire

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:16AM EDT Credit Suisse Initiates Coverage On Seagen with Neutral Rating, Announces Price Target of $145 Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

02:30AM EDT Astellas Pharma Inc. and Seagen Inc. (SGEN) said that the European Medicines Agency or EMA accepted a marketing authorization application for enfortumab vedotin. Enfortumab vedotin will be reviewed under accelerated assessment for the treatment of locally advanced or metastatic urothelial cancer. RTTNews

02:05AM EDT Astellas Pharma And Seagen: MAA For Enfortumab Vedotin Accepted By European Medicines Agency RTTNews

02:01AM EDT European Medicines Agency Accepts Marketing Authorization Application for PR Newswire

02:00AM EDT European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin Business Wire

Mar 25, 2021

08:04AM EDT UPDATE: Seagen Made Equity Investment In Pieris Via Purchase Of 3.7M Shares At $3.51/Share Benzinga

08:03AM EDT Pieris Reports Amendment To Existing Immuno-oncology Multi-Target Collab With Seagen, $13M Strategic Investment By Seagen Benzinga

Mar 5, 2021

08:03AM EST Seagen Recommends Rejection Of 'Mini-Tender' Offer From TRC Capital Investment RTTNews

08:00AM EST Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation Business Wire

Feb 24, 2021

08:00AM EST Seagen to Present at the Cowen 41st Annual Healthcare Conference Business Wire

Feb 22, 2021

04:47PM EST Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment Benzinga

Feb 18, 2021

08:56AM EST Seagen/Astellas Pharma Seek Approval For PADCEV's Expanded Use In Urothelial Cancer Settings Benzinga

08:02AM EST Astellas And Seagen Submit Two SBLAs To FDA For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer RTTNews

08:01AM EST Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV in Locally Advanced or Metastatic Urothelial Cancer Benzinga

08:00AM EST Applications to the U.S. FDA for PADCEV(r) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire

08:00AM EST Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV(r) (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer Business Wire

Feb 16, 2021

11:17AM EST RBC Capital Maintains Sector Perform on Seagen, Lowers Price Target to $169 Benzinga

Feb 12, 2021

02:17PM EST Seagen, Astellas Say Phase 3 Trial Results Demonstrate 'Survival Advantage' Of PADCEV In Patients With Previously Treated Advanced Urothelial Cancer Benzinga

02:15PM EST Advantage of PADCEV(r) (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer PR Newswire

02:15PM EST vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy PR Newswire

02:15PM EST Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV(r) (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer Business Wire

02:15PM EST Seagen and Astellas Announce Presentation of Results from PADCEV(r) (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy Business Wire

10:55AM EST Barclays Maintains Equal-Weight on Seagen, Lowers Price Target to $168 Benzinga

09:07AM EST Piper Sandler Maintains Neutral on Seagen, Lowers Price Target to $170 Benzinga

08:44AM EST Morgan Stanley Maintains Equal-Weight on Seagen, Lowers Price Target to $173 Benzinga

08:44AM EST 10 Biggest Price Target Changes For Friday Benzinga

08:16AM EST Seagen's TUKYSA Wins European Approval For Metastatic Breast Cancer Benzinga

06:58AM EST Seagen Inc. (SGEN) said Friday that the European Commission has granted marketing authorization for Tukysa or tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens. RTTNews

06:48AM EST Seagen: EC Grants Marketing Authorization For TUKYSA In Combination With Trastuzumab And Capecitabine RTTNews

06:45AM EST Seagen Reports European Commission Has Approved Co.'s TUKYSA For Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Benzinga

06:45AM EST European Commission Approves Seagen's TUKYSA(r) (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire

06:07AM EST SVB Leerink Maintains Outperform on Seagen, Lowers Price Target to $192 Benzinga

Feb 11, 2021

04:16PM EST Seattle Genetics Inc. (SGEN) released earnings for its fourth quarter that rose from the same period last year. RTTNews

04:07PM EST Seagen Q4 EPS $0.90 Vs. $0.14 Year Ago RTTNews

04:04PM EST Seagen Sees FY21 Sales: ADCETRIS Net Product Sales $675M-$700M, PADCEV Net Product Sales $310M-$327M, TUKYSA Net Product Sales $300M-$315M Benzinga

04:03PM EST Seattle Genetics Q4 EPS $0.90 Beats $0.86 Estimate, Sales $601.29M Beat $586.57M Estimate Benzinga

04:02PM EST Seagen Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

03:51AM EST Earnings Scheduled For February 11, 2021 Benzinga

Feb 10, 2021

04:22PM EST Seagen, Genmab Report Submission Of Tisotumab Vedotin Biologics License Application To US FDA For Patients With Recurrent, Metastatic Cervical Cancer Benzinga

04:10PM EST Seagen And Genmab A/S Announce Submission Of BLA To FDA Seeking Accelerated Approval For Tisotumab Vedotin RTTNews

04:05PM EST Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Business Wire

Feb 1, 2021

10:03AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2021 Benzinga

08:40AM EST RBC Capital Downgrades Seagen to Sector Perform, Lowers Price Target to $186 Benzinga

Jan 19, 2021

10:01AM EST Morgan Stanley Maintains Equal-Weight on Seagen, Raises Price Target to $177 Benzinga

Jan 15, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021 Benzinga

07:31AM EST B of A Securities Upgrades Seagen to Buy Benzinga

Jan 7, 2021

08:00AM EST Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021 Business Wire

Dec 31, 2020

04:41PM EST 'Halftime Report' Traders Advise Viewers On Salesforce, Netflix And More Benzinga

Dec 29, 2020

04:57PM EST Seagen S-3 Shows Registration For Mixed Securities Shelf Offering, No Size Disclosed Benzinga

Dec 16, 2020

08:00AM EST Seagen to Present at the J.P. Morgan Healthcare Conference Business Wire

Dec 11, 2020

07:42AM EST Biotechnology company Seagen Inc. (SGEN) said Friday that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion for TUKYSA (tucatinib) for the treatment of patients with locally advanced or metastatic HER2-Positive breast cancer. RTTNews

07:26AM EST Seagen Reports Positive CHMP Opinion For TUKYSA For Locally Advanced Or Metastatic HER2-Positive Breast Cancer RTTNews

07:24AM EST Seagen Announces Positive CHMP Opinion For TUKYSA For Treatment Of Patients With Locally Advanced Or Metastatic HER2-Positive Breast Cancer Benzinga

07:23AM EST Seagen Announces Positive CHMP Opinion for TUKYSA(r) (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire

Dec 8, 2020

08:08AM EST Seagen Announces Presentation Of New Data From TUKYSA At SABCS Symposium RTTNews

08:00AM EST Seagen Highlights TUKYSA(r) (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium Business Wire

Dec 7, 2020

10:08AM EST Seagen Announces Multiple ADCETRIS Presentations At ASH Benzinga

10:08AM EST Seagen Reports Multiple ADCETRIS Presentations At the 2020 ASH Annual Meeting RTTNews

10:00AM EST Seagen Announces Multiple ADCETRIS(r) (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting Business Wire

Nov 17, 2020

07:56AM EST 07:56 Tuesday, November 17, 2020William Blair (RTTNews) - William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform RTTNews

Nov 9, 2020

08:23AM EST Seagen Highlights Immuno-Oncology Data From Broad Portfolio During SITC Virtual Annual Meeting 2020 Benzinga

08:07AM EST Seagen Presents Immuno-Oncology Data From Broad Portfolio During SITC Virtual Annual Meeting 2020 RTTNews

08:00AM EST Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020 Business Wire

Nov 5, 2020

08:16AM EST Seagen Announces Multiple ADCETRIS Presentations At Upcoming ASH Annual Meeting Benzinga

08:00AM EST Seagen Announces Multiple ADCETRIS(r) (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting Business Wire

Nov 2, 2020

08:00AM EST Seagen to Host Virtual R&D Day on November 16, 2020 Business Wire

Oct 30, 2020

10:07AM EDT Shares of Seagen Inc. (SGEN) are losing more than 9 percent or $17.43 in Friday's morning trade at $174.91 despite the biotechnology company's third-quarter results beating analysts' estimates. RTTNews

09:16AM EDT Morgan Stanley Maintains Equal-Weight on Seagen, Raises Price Target to $175 Benzinga

07:05AM EDT SVB Leerink Maintains Outperform on Seagen, Lowers Price Target to $200 Benzinga

Oct 29, 2020

04:16PM EDT Seagen Cuts FY20 Sales From $675M-$700M To $650M-$660M Benzinga

04:14PM EDT Seagen Q3 EPS $3.50 Up From $(0.55) YoY, Sales $1.06B Up From $213.26M YoY Benzinga

04:13PM EDT Seagen Q3 EPS $3.50 Vs. Loss $0.55 Year Ago RTTNews

04:02PM EDT Seagen Reports Third Quarter 2020 Financial Results Business Wire

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 28, 2020

08:05AM EDT Seagen Reports Closing Of $1.0 Bln Stock Sale To Merck RTTNews

08:01AM EDT Seagen Announces Closing of $1.0 Billion Stock Sale to Merck Business Wire

Oct 20, 2020

06:09AM EDT Seagen On Oct. 19 Filed Complaint In Court Against Daiichi Sankyo To Commence An Action For Infringement Benzinga

Oct 15, 2020

11:06AM EDT B of A Securities Maintains Neutral on Seagen, Raises Price Target to $215 Benzinga

Oct 14, 2020

03:43PM EDT 'Halftime Report Traders' Share Their Thoughts On Target, Johnson & Johnson And More Benzinga

Oct 13, 2020

08:00AM EDT Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020 Business Wire

Oct 12, 2020

09:44AM EDT SVB Leerink Maintains Outperform on Seagen, Raises Price Target to $204 Benzinga

06:51AM EDT Astellas, Seagen Announce Positive Topline Results From Second Cohort Of Patients In Phase 2 Pivotal Trial Of PADCEV RTTNews

06:46AM EDT Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV in Advanced Urothelial Cancer Benzinga

06:45AM EDT Patients in Phase 2 Pivotal Trial of PADCEV(r) (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer PR Newswire

06:45AM EDT Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV(r) (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer Business Wire

Oct 8, 2020

08:07AM EDT Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc. Benzinga

08:04AM EDT Seattle Genetics, Inc. Changes Corporate Name To Seagen Inc.; Ticker Symbol To Continue Under "SGEN" RTTNews

08:00AM EDT Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc. Business Wire

Oct 5, 2020

03:17PM EDT 'Fast Money Halftime Report' Picks For October 5 Benzinga

Sep 22, 2020

08:16AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

06:08AM EDT SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to $187 Benzinga

Sep 21, 2020

10:26AM EDT Seattle, Genmab Present Data From Tisotumab Vedotin InnovaTV 204 Trial In Recurrent Or Metastatic Cervical Cancer RTTNews

10:22AM EDT Seattle Genetics, Genmab Present Data From Tisotumab Vedotin InnovaTV 204 Pivotal Trial In Recurrent Or Metastatic Cervical Cancer At ESMO Virtual Congress 2020 Benzinga

Sep 18, 2020

07:16AM EDT Biotechnology company Seattle Genetics, Inc. (SGEN) and Japanese pharmaceutical company Astellas Pharma Inc. (ALPMY, ALPMY) announced Friday that a phase 3 trial of PADCEV (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. RTTNews

06:51AM EDT Seattle Genetics And Astellas Pharma Announce Phase 3 Trial Of PADCEV Meets Primary Endpoint RTTNews

06:46AM EDT Seattle Genetics, Astellas Reports PADCEV Significantly Improves Overall Survival In Phase 3 Trial In Previously Treated Locally Advanced, Metastatic Urothelial Cancer Benzinga

06:45AM EDT Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer PR Newswire

06:45AM EDT Seattle Genetics and Astellas Announce PADCEV(r) (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer Business Wire

Sep 15, 2020

11:43AM EDT RBC Capital Maintains Outperform on Seattle Genetics, Raises Price Target to $191 Benzinga

08:19AM EDT 10 Biggest Price Target Changes For Tuesday Benzinga

07:45AM EDT Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Raises Price Target to $167 Benzinga

06:20AM EDT SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to $185 Benzinga

Sep 14, 2020

09:57AM EDT Shares of Seattle Genetics Inc. (SGEN) are rising more than 10 percent or $15.18 in Monday's morning trade at $165.15 after the company and Merck & Co. Inc (MRK) announced two new strategic oncology collaborations that includes a $1 billion equity investment by Merck in Seattle Genetics. RTTNews

09:51AM EDT Looking Into Seattle Genetics's Return On Capital Employed Benzinga

07:08AM EDT Seattle Genetics, Inc. (SGEN) and Merck (MRK), known as MSD outside the U.S. and Canada, announced on Monday two new strategic oncology collaborations. RTTNews

06:52AM EDT Seattle Genetics, Merck Announce Strategic Oncology Collaborations; Merck To Buy $1 Bln Equity Stake In Seattle Genetics RTTNews

06:47AM EDT Seattle Genetics and Merck Announce Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe Benzinga

06:45AM EDT Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations Business Wire

Sep 3, 2020

08:00AM EDT Seattle Genetics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference Business Wire

Aug 27, 2020

08:25AM EDT Seattle Genetics Highlights Data From Broad Oncology Portfolio During ESMO Virtual Congress 2020; Reports Positive Tisotumab Vedotin Phase 2 InnovaTV 204 Data In Recurrent Or Metastatic Cervical Cancer Benzinga

08:22AM EDT Seattle Genetics To Receive Milestone Payment Under ADC Collaboration With GlaxoSmithKline Following European Commission Approval of BLENREP Benzinga

08:13AM EDT Seattle Genetics To Receive Milestone Payment From GlaxoSmithKline Under ADC Collaboration RTTNews

08:10AM EDT Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin) Business Wire

08:09AM EDT Seattle Genetics Highlights Data From Broad Oncology Portfolio During ESMO Virtual Congress 2020 RTTNews

Aug 18, 2020

08:00AM EDT Seattle Genetics Appoints Ted W. Love, M.D., to Board of Directors Business Wire

Aug 12, 2020

08:06AM EDT Seattle Genetics Says TUKYSA Approved Within Months For All Countries Participating In FDA's Project Orbis Initiative RTTNews

08:02AM EDT Seattle Genetics Announces TUKYSA Approved For All Countries Participating In FDA's Project Orbis Initiative Benzinga

08:00AM EDT Seattle Genetics Announces TUKYSA(r) (tucatinib) Approved Within Months for All Countries Participating in FDA's Project Orbis Initiative Business Wire

Aug 6, 2020

08:04AM EDT Seattle Genetics Reports Trigger Of $20M Milestone Payment Related To Collaboration With GlaxoSmithKline For BLENREP FDA Approval Benzinga

08:00AM EDT Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval Business Wire

Jul 31, 2020

09:04AM EDT Morgan Stanley Maintains Equal-Weight on Seattle Genetics, Raises Price Target to $160 Benzinga

06:43AM EDT SVB Leerink Maintains Outperform on Seattle Genetics, Raises Price Target to $173 Benzinga

06:12AM EDT HC Wainwright & Co. Maintains Buy on Seattle Genetics, Raises Price Target to $200 Benzinga

Jul 30, 2020

04:06PM EDT Seattle Genetics Q2 Loss/share $0.12 Vs. Loss $0.49 Year Ago RTTNews

04:04PM EDT Seattle Genetics Sees FY20 ADCETRIS Net Product Sales $675M-$700M Benzinga

04:03PM EDT Seattle Genetics Q2 EPS $(0.12) Beats $(0.63) Estimate, Sales $278.00M Beat $256.06M Estimate Benzinga

04:02PM EDT Seattle Genetics Reports Second Quarter 2020 Financial Results Business Wire

04:06AM EDT Earnings Scheduled For July 30, 2020 Benzinga

Jul 29, 2020

07:12AM EDT Nura Bio Launches to Discover and Develop Neuroprotective Drugs, Backed by $73 Million Series A Financing Benzinga

Jul 24, 2020

12:10PM EDT Piper Sandler Downgrades Seattle Genetics, Says Visibility Limited On Value Creation Benzinga

08:13AM EDT 10 Biggest Price Target Changes For Friday Benzinga

06:13AM EDT A Peek Into The Markets: US Stock Futures Down Following Thursday's Sell-Off Benzinga

05:05AM EDT Piper Sandler Downgrades Seattle Genetics to Neutral, Raises Price Target to $165 Benzinga